Sitemap
- Company
- Press releases
- Europe
- DAIICHI SANKYO remains on growth course in Europe
- First new drug application for oral factor Xa inhibitor edoxaban
- International Women's Day
- HOKUSAI VTE
- Archive 2009
- "Improvement through Movement"
- Alliance between MorphoSys and DAIICHI SANKYO
- Launch of EVISTA® in Eastern Europe
- Edoxaban - ESC Barcelona
- FDA approval for EFFIENT®
- High growth in sales and employee numbers
- Best Cardiovascular Pipeline
- Time for change - International Womens Day
- DAIICHI SANKYO takes over cardiovascular sales force from Merck Serono in Italy
- European Commission Approves EFIENT® (prasugrel)
- DAIICHI SANKYO appoints Managing Director for Ireland
- Blood pressure goal missed by two thirds of patients
- Archive 2008
- DAIICHI SANKYO's Prasugrel receives positive opinion from the EU-Committee
- DAIICHI SANKYO to acquire sales force from Merck Serono in France
- DAIICHI SANKYO initiates Phase III trial of its investigational Factor Xa inhibitor
- New Phase II data provide insight into optimal dosing of oral Factor Xa inhibitor
- DAIICHI SANKYO sets up subsidiary in Ireland
- Marketing approval for SEVIKAR® granted
- DAIICHI SANKYO enters strategic R&D partnership with ArQule
- DAIICHI SANKYO restructures European affiliates
- DAIICHI SANKYO acquires Merck Serono’s sales force and products in Turkey
- DAIICHI SANKYO announces clinical study data for DU-176b
- DAIICHI SANKYO appoints general manager in Turkey
- DAIICHI SANKYO plans to obtain sales force from Merck Pharma GmbH
- DAIICHI SANKYO to implement carbon offset program
- DAIICHI SANKYO joins the IFPMA
- FDA Extends Review Period for Prasugrel
- OLMETEC® opens narrowed arteries in patients with hypertension
- Ranbaxy to bring in DAIICHI SANKYO as Majority Partner
- DAIICHI SANKYO aquires U3 Pharma
- DAIICHI SANKYO sets up affiliate in Turkey
- DAIICHI SANKYO presses ahead with European expansion
- FDA grants priority review for prasugrel
- MAA submission of prasugrel
- DAIICHI SANKYO Submit New Drug Application...
- Archive 2007
- New Prasugrel Head-to-Head Study
- Phase III Head-to-Head Study
- Two small early-phase PRASUGREL studies..
- New product under development....
- DAIICHI SANKYO is expanding its production capacities
- Merger for worldwide growth completed
- Midterm Management Plan
- Enrollment Phase III Completed...
- New study shows Prasugrel...
- Archive 2006
- Social Engagement
- Tokyo
- US
- Media Contact
- Download center
- Europe








